- Home
- NAK vs TRVI Comparison
NAK vs TRVI Comparison
Compare NAK & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAK | TRVI |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.4M | 1.4B |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NAK | TRVI |
|---|---|---|
| Price | $1.91 | $13.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $2.50 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 8.3M | 1.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $5.38 |
| 52 Week High | $2.98 | $14.39 |
Technical Indicators
Market Signals| Indicator | NAK | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 70.29 |
| Support Level | $1.83 | $10.07 |
| Resistance Level | $2.37 | N/A |
| Average True Range (ATR) | 0.12 | 0.90 |
| MACD | 0.08 | 0.23 |
| Stochastic Oscillator | 92.09 | 98.30 |
Price Performance
Historical ComparisonAbout NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.